Investigation of picroside II's impacts on the P450 activities using a cocktail method

Chinese Journal of Natural Medicines

Volumn 6, Issue 4, 2008, Pages 292-297

  Xiao, Ya Jie ^a   Jiang, Zhen Zhou ^a   Yao, Jin Cheng ^a   Huang, Xin ^a   Huang, Jing Feng ^a   Wang, Tao ^a   Zhang, Lu Yong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cocktail; P450; Picroside II; Probe drug

Indexed keywords

ANTIOXIDANT; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; MIDAZOLAM; OMEPRAZOLE; PICROSIDE II;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE;

EID: 48749124128     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.3724/SP.J.1009.2008.00292     Document Type: Article

References (21)

1. Jia Q, Hong MF, Minter D. Pikuroside: A Novel Iridoid from Picrorhiza kurroa[J]. J Nat Prod, 1999, 62(6): 901-903.
2. Li P, Matsunaga K, Yamakuni T, et al Picrosides I and II, selective enhancers of the mitogen-activated protein kinase-dependent signaling pathway in the action of neuritogenic substances on PC12D cells [J]. Life Sci, 2002, 71(15): 1821-1835.
3. Li T, Liu JW, et al. The neuroprotective effect of picroside II from hu-huang-lian against oxidative stress [J]. Am J Chin Med, 2007, 35(4): 681-691.
4. Gao H, Zhou YW. Inhibitory effect of picroside II on hepatocyte apoptosis [J]. Acta Pharmacol Sin, 2005, 26(6): 729-736.
5. Kiso Y, Tohkin M, Hikino H. Assay method for antihepatotoxic activity using galactosamine-induced cytotoxicity in primary-cultured hepatocytes [J]. J Nat Prod, 1983, 46(6): 841-847.
6. Li P, Matsunaga K, Ohizumi Y. Nerve growth factor-potentiating compounds from Picrorhizae Rhizoma [J]. Biol Pharm Bull, 2000, 23(7): 890-892.
7. Li P, Matsunaga K, Yamakuni T, et al Potentiation of nerve growth factor-action by picrosides I and H, natural iridoids, in PC 12D cells [J]. Eur J Pharmacol, 2000, 406(2): 203-208.
8. Yang FC, Yang SL, Xu LZ. Determination of picroside II in dog plasma by HPLC and its application in a pharmacokinetics study [J]. Biomed Chromatogr, 2005, 19(4): 279-284.
9. Gao H, Zhou YW. Anti-lipid peroxidation and protection of liver mitochondria against injuries by picroside II [J]. World J Gastroenterol, 2005, 11(24): 3671-3674.
10. Lv J, Pan L, Ye Y, et al A sensitive and selective RP-HPLC method for simultaneous determination of picroside-I and picroside-II in rat plasma and its application in pharmacokinetics studies [J]. J Sep Sci, 2007, 30(15): 2466-2472.
11. Honig PK, Wortham DC, Zamani K, et al Terfenadine ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences [J]. JAMA, 1993, 269(12): 1513-1518.
12. Ball SE, Ahern D, Scatina J, et al Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2 [J]. Br J Clin Pharmacol, 1997, 43(6): 619-626.
13. Ko JW, Sukhova N, Thacker D, et al Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms [J]. Drug Metab Dispos, 1997, 25(7): 853-862.
14. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies [J]. JAMA, 1993, 269(12): 1550-1552.
15. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al Effect of propiverine on cytochrome P450 enzymes: a cock- tail interaction study in healthy volunteers [J], Drug Metab Dispos, 2005, 33(12): 1859-1866.
16. Smith D, Sadagopan N, Zientek M, et al Analytical ap- proaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 850(1-2): 455-463.
17. Chow HH, Hakim IA, Vining DR, et al Effects of repeated green tea catechin administration on human cytochrome P450 activity [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(12): 2473-2476.
18. Bruce MA, Hall SD, Haehner-Daniels BD, et al In vivo ef- fect of clarithromycin on multiple cytochrome P450s [J]. Drug Metab Dispos, 2001, 29(7): 1023-1028.
19. Krösser S, Neugebauer R, Dolgos H, et al Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial [J]. Eur J Clin Pharmacol, 2006, 62(4), 277-284.
20. Frye RF, Branch RA. Effect of chronic disulfiram admini- stration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects [J]. Br J Clin Pharmacol, 2002, 53(2): 155-162.
21. Provencher SJ, Demers C, Bastien MC, et al Effect of cyc- losporine A on cytochrome P-450-mediated drug metabolism in the partially hepatectomized rat [J]. Drug Metab Dispos, 1999, 27(4): 449-455. gd